Maxim Group reaffirmed their buy rating on shares of OncoSec Medical Incorporated (NASDAQ:ONCS) in a research note published on Tuesday. They currently have a $5.00 target price on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of OncoSec Medical from a strong sell rating to a sell rating in a research note on Friday, July 14th. Dawson James reiterated a buy rating and issued a $5.00 price target on shares of OncoSec Medical in a research note on Thursday, July 6th. Noble Financial reiterated a buy rating on shares of OncoSec Medical in a research note on Wednesday, June 14th. Finally, HC Wainwright set a $6.00 price target on shares of OncoSec Medical and gave the stock a buy rating in a research note on Monday, June 12th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. OncoSec Medical has an average rating of Buy and a consensus price target of $5.33.

OncoSec Medical (NASDAQ:ONCS) traded down 1.00% on Tuesday, hitting $0.99. 165,808 shares of the company traded hands. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.08. The firm’s market capitalization is $20.96 million. The stock’s 50-day moving average is $0.99 and its 200 day moving average is $1.07.

ILLEGAL ACTIVITY WARNING: “OncoSec Medical Incorporated (ONCS) Receives Buy Rating from Maxim Group” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.